Hepatitis C

A cascade-of-care analysis of the country's largest tribally-operated health system showed clear gaps in progressing patients with HCV from diagnosis to completed treatment.

The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.

There were several risk factors identified, including abortion, hospitalization, past surgical procedure, dental extraction, delivery in hospital, injection in hospitals, and household contact with jaundice.

A beta diversity analyses revealed a distinct clustering pattern between healthy controls and patients with HBV-related liver disease and the composition of bacteria from the phylum level to the genus level varies across the stages of liver disease.

The results show a moderate certainty on the lack of effect across outcomes and 2 values and preferences studies found participants enjoyed specific counseling behavioral interventions.

Individuals who sought outpatient mental health and addiction services were generally younger, proportionately more female, more likely to have a psychiatric comorbidity, and more likely to have had their index alcohol-related hospitalization attributed to than to other diagnoses such as harmful alcohol use or alcoholic liver disease.

There was an association between NAFLD in the South-Asian population and diabetes mellitus, hypertension, dyslipidemia, general obesity, central obesity and metabolic syndrome.

The prevalence rate was the highest in methadone clinics followed by correctional institutions, HIV clinics, and the surveillance program.

There is no additional risk of developing new cancers for patients treated with IBD medications.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

The 2030 goal for global elimination of HCV looks out of reach so as key patient population including those who inject drugs are out of clinician's reach, one expert explains.

Patients with moderate to severe PCM to go along with the AAH were significantly more likely have a number of vitamin deficiencies, including in vitamin D, vitamin B12, and folate.

The investigators also found impaired biosynthesis of short-chain fatty acids in the coprofiltrate after analyzing the intestinal microbiome of patients with NAFLD who had SARS-CoV-2, manifested by an increase in the median acetic and propionic acids, as well as a decrease in the median butyric acid.

Counties with high liver transplantation registration rates and high liver-related mortality rates had comparable data on social vulnerability index, while travel distance was relatively shorter.

All countries in Africa now provide a three-dose infant hepatitis B vaccination beginning at age 6-8 weeks.

There is some concern that the prevalence of diseases like NASH and NAFLD may increase in the coming years.

The SVR rates remained consistently high after the investigators conducted a subgroup analysis stratified by genotype, treatment duration, fibrosis stage, and concomitant medications.

National data show mortality rates climbed 23% in 2020, primarily driven by increases among American Indian or Alaska Native people.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

Some traditional sarcopenia assessment techniques included direct measurements on cross sectional imaging, but cross sectional imaging also comes with increased time, cost, and radiation exposure.

Using the bidirectional Montreal classification system, which accounts for disease regression, showed that 90% of patients exhibited inflammatory disease behavior at 5 years, compared to 58% if the hierarchical, unidirectional Montreal classification system was implemented.

April is Donate Life Month, where many advocate for more living organ donors.

Of the patients in the first cohort, 0.7% had HBV, all of which had a history of drug use. In addition, 3% were anti-HCV positive, 8 of which had a history of drug.

Metabolic dysfunction was associated with increased risk of HCC, while patients with only metabolic dysfunction had the highest risk because the sustained virological response achievement.

The cumulative probabilities of treatment initiation after meeting the criteria was not significantly different between the different racial groups and the incidence of major adverse liver outcomes was 0.1 per 100 person-years and did not differ by race.

The investigators found having at least 1 risk factor increased the odds of having an HCV-positive result by 20% compared to the population without risk factors.

The proportion of AUD treatment engagement did not differ between the 2 time periods, but intervention increased intermediate outcomes, including screening, new AUD diagnosis, and treatment initiation.

A nearly two-fold increase or decrease in liver stiffness would be required to confidently represent a change in the underlying fibrosis.

There was an 88.12% cure rate in the intention-to-treat analysis.

There is a June 22 PDUFA date for obeticholic acid, which if approved would become the first FDA-approved treatment for NASH.